{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T14:28:01Z","timestamp":1776954481605,"version":"3.51.4"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The duration of initial corticosteroid therapy in newly diagnosed Idiopathic nephrotic syndrome (INS) is about 3 months. Our study was designed to test the feasibility of a shorter duration of corticosteroid therapy in newly diagnosed INS who show a quicker response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients who responded within 10 days (Group A) received 8 weeks of corticosteroid therapy as compared to 12\u201314 weeks of standard therapy in those who responded between &amp;gt;10 days to 28 days (Group B), and follow up for 52 weeks. The primary endpoint is time to first relapse after treatment completion. (NCT03878914, March 18, 2019)<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 33 children with INS were enrolled and the follow-up data were analyzed. The clinical and laboratory characteristics of patients in both groups were similar. No significant difference was found in time to first relapse [65(14.5, 159) days for Group A vs. 28(17, 61.5) days for Group B, <jats:italic>P\u2009=\u20090.371<\/jats:italic>], the incidence of frequently relapsing nephrotic syndrome [6\/18 (33.3%) vs. 5\/10(50%), <jats:italic>P\u2009=\u20090.644<\/jats:italic>] or requirement for alternative immunosuppressant [4\/18 (22.2%) vs. 1\/10 (10%), <jats:italic>P\u2009=\u20090.769<\/jats:italic>]. Group A received similar corticosteroid dose compare with Group B (3511\u2009\u00b1\u20092421\u2005mg\/m<jats:sup>2<\/jats:sup> vs. 4117\u2009\u00b1\u20092556\u2005mg\/m<jats:sup>2<\/jats:sup>, <jats:italic>P\u2009=\u20090.524<\/jats:italic>). Frequency and severity of corticosteroid-related complications was similar in both groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The time to first relapse and the number of relapses per patient were comparable between the two groups. However, more patients in Group A relapsed and the mean total dose of prednisolone for the study period was very similar between the two groups.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.1043285","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T07:34:50Z","timestamp":1667374490000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Duration of initial prednisolone therapy for first episode of childhood nephrotic syndrome based on time to response"],"prefix":"10.3389","volume":"10","author":[{"given":"Xiaoshan","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manpreet","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tej","family":"Mattoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","article-title":"Idiopathic nephrotic syndrome in children","volume":"392","author":"Noone","year":"2018","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2215\/CJN.05691108","article-title":"Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children","volume":"4","author":"Kyrieleis","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0022-3476(79)80660-5","article-title":"International Study of Kidney Disease in Children. Nephrotic syndrome in children: a randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. Report of the international study of kidney disease in children","volume":"95","year":"1979","journal-title":"J Pediatr"},{"key":"B4","doi-asserted-by":"publisher","first-page":"CD001533","DOI":"10.1002\/14651858.CD001533.pub6","article-title":"Corticosteroid therapy for nephrotic syndrome in children","volume":"2020","author":"Hahn","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1542\/peds.105.3.492","article-title":"Predicting first-year relapses in children with nephrotic syndrome","volume":"105","author":"Constantinescu","year":"2000","journal-title":"Pediatrics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s004670100024","article-title":"Risk factors for steroid dependency in children with idiopathic nephrotic syndrome","volume":"16","author":"Yap","year":"2001","journal-title":"Pediatr Nephrol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jpeds.2009.12.020","article-title":"Time for initial response to steroids is a major prognostic factor in idiopathic nephrotic syndrome","volume":"156","author":"Vivarelli","year":"2010","journal-title":"J Pediatr"},{"key":"B9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00467-018-4095-z","article-title":"B cell phenotype in pediatric idiopathic nephrotic syndrome","volume":"34","author":"Colucci","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00467-017-3677-5","article-title":"Immunology of idiopathic nephrotic syndrome","volume":"33","author":"Colucci","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000511319","article-title":"Decreased circulating transitional B-cell to memory B-cell ratio is a risk factor for relapse in children with steroid-sensitive nephrotic syndrome","volume":"145","author":"Ling","year":"2021","journal-title":"Nephron"},{"key":"B12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1053\/j.ajkd.2017.10.013","article-title":"HLA-DQA1 and APOL1 as risk loci for childhood-onset steroid-sensitive and steroid-resistant nephrotic syndrome","volume":"71","author":"Adeyemo","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1681\/ASN.2014030247","article-title":"HLA-DQA1 and PLCG2 are candidate risk loci for childhood-onset steroid-sensitive nephrotic syndrome","volume":"26","author":"Gbadegesin","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/ki.2014.260","article-title":"A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment","volume":"87","author":"Yoshikawa","year":"2015","journal-title":"Kidney Int"},{"key":"B15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/ki.2014.240","article-title":"Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome","volume":"87","author":"Sinha","year":"2015","journal-title":"Kidney Int"},{"key":"B16","doi-asserted-by":"publisher","first-page":"l1800","DOI":"10.1136\/bmj.l1800","article-title":"Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation","volume":"365","author":"Webb","year":"2019","journal-title":"Br Med J"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1043285\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T07:34:52Z","timestamp":1667374492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1043285\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":16,"alternative-id":["10.3389\/fped.2022.1043285"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.1043285","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"article-number":"1043285"}}